<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Cipla</title>
	<atom:link href="http://www.tapanray.in/tag/cipla/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India’s China Dependence On API: A Time To Think ‘Outside The Box’</title>
		<link>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-china-dependence-on-api-a-time-to-think-outside-the-box</link>
		<comments>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/#comments</comments>
		<pubDate>Mon, 21 Sep 2015 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[Advisor]]></category>
		<category><![CDATA[Ananth Kumar]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[dependence]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Katoch]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[out of box]]></category>
		<category><![CDATA[outside]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[year of API]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7086</guid>
		<description><![CDATA[The Department of Pharmaceuticals (DoP) has declared the Year 2015 as the Year of ‘Active Pharmaceutical Ingredient (API)’. Following it up on February 25, 2015, the Union Minister of Chemicals &#38; Fertilizers Ananth Kumar assured the Pharmaceutical Industry that appropriate &#8230; <a href="http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-china-dependence-on-api-a-time-to-think-outside-the-box/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Patent Linkage’: Can The Core Issue Be Resolved?</title>
		<link>http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-linkage-can-the-core-issue-be-resolved</link>
		<comments>http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/#comments</comments>
		<pubDate>Mon, 23 Feb 2015 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[administrative]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Arun]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[Corporation]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Froman]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Jaitley]]></category>
		<category><![CDATA[Kher]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[measures]]></category>
		<category><![CDATA[Mike]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pratibha]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[rajiv]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[RTI]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[status]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[visit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6392</guid>
		<description><![CDATA[On February 10, 2015, a leading business daily of India, quoted the Commerce Secretary of India &#8211; Rajeev Kher, saying, “India needs to relook at its Intellectual Property Rights (IPR) Policy with a view to bring in a differentiated regime &#8230; <a href="http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Awaiting ‘The Moment of Truth’ on ‘Working of Patents’ in India</title>
		<link>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=awaiting-the-moment-of-truth-on-working-of-patents-in-india</link>
		<comments>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/#comments</comments>
		<pubDate>Mon, 03 Nov 2014 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Form 27]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[Indacaterol]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[inventive]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Onbrez]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Section 66]]></category>
		<category><![CDATA[Section 92]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[truth]]></category>
		<category><![CDATA[Unibrez Rotacaps]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6148</guid>
		<description><![CDATA[By a letter dated October 21, 2014 addressed to the Secretary, Department of Industrial Policy and Promotion (DIPP) of India, the domestic pharma major Cipla has sought for the revocation of five patents of Novartis AG’s respiratory drug Indacaterol (Onbrez) in India, &#8230; <a href="http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/awaiting-the-moment-of-truth-on-working-of-patents-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gilead: Caught Between A Rock And A Hard Place In India</title>
		<link>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gilead-caught-between-a-rock-and-a-hard-place-in-india</link>
		<comments>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/#comments</comments>
		<pubDate>Mon, 22 Sep 2014 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alliance]]></category>
		<category><![CDATA[Between. Rock]]></category>
		<category><![CDATA[Cadila Healthcare]]></category>
		<category><![CDATA[Caught]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[Hetero labs and Sequent Scientific]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO. Indian]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[monopolies]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Place]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Strides Arcolab]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tenofovir]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6001</guid>
		<description><![CDATA[I had mentioned in my blog post of August 4, 2014, titled “Hepatitis C: A Silent, Deadly Disease: Treatment beyond reach of Most Indians” that in line with Gilead’s past approach to its HIV medicines, the company would offer to &#8230; <a href="http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does Patent Expiry Matter Less For Difficult To Copy Drugs?</title>
		<link>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-patent-expiry-matter-less-for-difficult-to-copy-drugs</link>
		<comments>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/#comments</comments>
		<pubDate>Mon, 08 Sep 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advair]]></category>
		<category><![CDATA[aerosol]]></category>
		<category><![CDATA[AirFluSal Forspiro]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[copy]]></category>
		<category><![CDATA[difficult]]></category>
		<category><![CDATA[Diskus]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inhaler]]></category>
		<category><![CDATA[less]]></category>
		<category><![CDATA[matters]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[ParaIV]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Seretide]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5865</guid>
		<description><![CDATA[“Patent expiry matters much less for difficult to copy drugs”. Not so long ago, this is what many used to believe in the pharma industry. However, looking at the current trend involving the tech savvy generic players, it appears, gone &#8230; <a href="http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-patent-expiry-matter-less-for-difficult-to-copy-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alarming Incidence of Cancer: Fragile Infrastructure: Escalating Drug Prices</title>
		<link>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices</link>
		<comments>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/#comments</comments>
		<pubDate>Mon, 28 Jul 2014 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[alarming]]></category>
		<category><![CDATA[ASCO]]></category>
		<category><![CDATA[Astellas Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Celgene]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[escalating]]></category>
		<category><![CDATA[evaluate]]></category>
		<category><![CDATA[fact]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incidence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance Life Science]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sheet]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Zydus Cadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5672</guid>
		<description><![CDATA[According to the &#8216;Fact-Sheet 2014&#8242; of the World Health Organization (WHO), cancer cases would rise from 14 million in 2012 to 22 million within the next two decades. It is, therefore, no wonder that cancers figured among the leading causes &#8230; <a href="http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Moving Up The Generic Pharma Value Chain</title>
		<link>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=moving-up-the-generic-pharma-value-chain</link>
		<comments>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/#comments</comments>
		<pubDate>Mon, 30 Jun 2014 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[BIPP]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fondaparinux]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GlobaData]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[moving]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Ohm]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[SBIRI]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Valcyte]]></category>
		<category><![CDATA[valsartan]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5565</guid>
		<description><![CDATA[June 2014 underscores a significant development for the generic drug exporters of India. Much-delayed and highly expected launch of generic Diovan (Valsartan) is now on its way, as Ranbaxy has reportedly received US-FDA approval to launch the first generic version of this blood pressure drug &#8230; <a href="http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Fire in The Blood”: A Ghastly Patents Vs Patients War &#8211; for Pricing Freedom?</title>
		<link>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom</link>
		<comments>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/#comments</comments>
		<pubDate>Mon, 07 Oct 2013 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[blood]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[CSR]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Dylan]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[ghastly]]></category>
		<category><![CDATA[Gray]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Mohan]]></category>
		<category><![CDATA[obscene]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[war]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3776</guid>
		<description><![CDATA[International award winning documentary film, &#8216;FIRE IN THE BLOOD&#8217; could possibly set a raging fire in your blood too, just like mine. It made me SAD, REFLECTIVE and ANGRY, prompting to share &#8216;MY TAKE AWAYS&#8217; with you on this contentious subject, immediately after I put &#8230; <a href="http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fire-in-the-blood-a-ghastly-patents-vs-patients-war-for-pricing-freedom/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India, China Revoke Four Pharma Patents in A Fortnight: A Double Whammy for MNCs?</title>
		<link>http://www.tapanray.in/india-china-revoke-four-pharma-patents-in-a-fortnight-a-double-whammy-for-mncs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-china-revoke-four-pharma-patents-in-a-fortnight-a-double-whammy-for-mncs</link>
		<comments>http://www.tapanray.in/india-china-revoke-four-pharma-patents-in-a-fortnight-a-double-whammy-for-mncs/#comments</comments>
		<pubDate>Mon, 12 Aug 2013 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Allergan]]></category>
		<category><![CDATA[angry]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Combigan]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[disputes]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[erlotinib]]></category>
		<category><![CDATA[Ganfort]]></category>
		<category><![CDATA[Gefitinib]]></category>
		<category><![CDATA[genuine]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hepatiris B]]></category>
		<category><![CDATA[Hetero]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[invention]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPAB]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[Iressa]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pegasys]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prevails]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revoked]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[SRT]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Sutent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tarceva]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Tykerb]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3326</guid>
		<description><![CDATA[Revocation of four pharma patents by India and China within a fortnight has raised many eyebrows, yet again, across the globe. In this short period, India has revoked three patents and China one. While this quick development is probably a &#8230; <a href="http://www.tapanray.in/india-china-revoke-four-pharma-patents-in-a-fortnight-a-double-whammy-for-mncs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-china-revoke-four-pharma-patents-in-a-fortnight-a-double-whammy-for-mncs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Glivec Like Deals in China and Mounting Global Challenges: Innovators poised Joining Biosimilar Bandwagon</title>
		<link>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon</link>
		<comments>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/#comments</comments>
		<pubDate>Mon, 15 Apr 2013 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12years]]></category>
		<category><![CDATA[AbVie]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bandwagon]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Genentech]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[joining]]></category>
		<category><![CDATA[LG]]></category>
		<category><![CDATA[low]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2164</guid>
		<description><![CDATA[Pressure from the emerging markets on pricing of patented products is mounting fast. This time the country involved is China. Recently, the Health Minister of China who stepped down last month after a seven-year stint in the top health job &#8230; <a href="http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
